# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Receptor Ledger · POMC & MC1R–MC5R Biology** · Dispatch 02 · Origin & Switchboard

---

[Melanotans](/) / Five Receptors

# One precursor gene, one four-amino-acid key, five very different organs

Every clinical advance and every off-target effect in melanocortin pharmacology begins with an evolutionary constraint: five related cell-surface switches recognize closely overlapping sequences cleaved from one precursor protein.

**Field Record 04 · Five Channels:** A single precursor protein ([POMC](https://pubmed.ncbi.nlm.nih.gov/9620771/)) yields the melanocortin ligands that signal across five receptor channels ([MC1R through MC5R](https://pubmed.ncbi.nlm.nih.gov/26916163/)), explaining why nonselective peptides spill across organs.

## How sunlight triggers the POMC precursor

Natural suntanning is a stress-response cascade, not a benign cosmetic glow. In 2007, biochemical and genetic experiments by Rutao Cui, David Fisher, and colleagues showed that [ultraviolet-induced pigmentation requires keratinocytes (outer skin cells) to secrete alpha-melanocyte-stimulating hormone (`α-MSH`) under the direct control of the tumor-suppressor protein p53](https://pubmed.ncbi.nlm.nih.gov/17350573/). When UV strikes skin DNA, p53 activates transcription of the pro-opiomelanocortin (`POMC`) gene; in knockout mice lacking p53, the UV-tanning response disappears. The same pathway also produces `β-endorphin`, which the authors note may contribute to sun-seeking behavior.

`POMC` acts as a biological precursor cut sequentially into distinct hormone families. As Heiko Krude and colleagues summarized in 1998, [sequential cleavage of pre-pro-opiomelanocortin generates the melanocortin peptides—adrenocorticotropic hormone (ACTH) and alpha-, beta-, and gamma-MSH—as well as the opioid-receptor ligand beta-endorphin](https://pubmed.ncbi.nlm.nih.gov/9620771/). Whereas `β-endorphin` signals through opioid receptors, the cleaved melanocortin peptides dock onto five closely related G protein-coupled receptors (GPCRs)—cell-surface proteins that thread across a cell membrane seven times to relay external chemical signals into intracellular messengers such as cyclic AMP.

**Figure 2 · One Precursor, Five Targets.** Cleaved `α-`, `β-`, and `γ-MSH` signal across MC1R, MC3R, MC4R, and MC5R; ACTH stimulates all five receptors and is the sole endogenous agonist for adrenal MC2R, requiring its first 17 amino acids. Sources: [Krude (1998)](https://pubmed.ncbi.nlm.nih.gov/9620771/), [Yang (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/), [Cai & Hruby (2016)](https://pubmed.ncbi.nlm.nih.gov/26916163/), [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/).

## Why receptor selectivity is chemically difficult

After the first melanocortin receptor genes were cloned by [Mountjoy, Cone, and colleagues in 1992](https://pubmed.ncbi.nlm.nih.gov/1325670/), sequence comparisons exposed why synthetic peptides cross between subtypes. Melanocortin receptors are [the smallest G protein-coupled receptors known](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/), and human subtypes share [38% to 60% sequence identity](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/)—highest between MC4R and MC5R (60%), 45% between MC3R and MC1R or MC2R, and lowest between MC2R and MC4R (38%).

Every natural melanocortin agonist derived from POMC carries the evolutionarily conserved [four-amino-acid sequence `His-Phe-Arg-Trp`](https://pubmed.ncbi.nlm.nih.gov/26916163/). Functional mapping reviewed by Yuan and Tao (2022) distinguishes each receptor's activation requirement: [`His-Phe-Arg-Trp` is the minimal MSH sequence required for MC1R, MC3R, and MC5R activation, three amino acids (`Phe-Arg-Trp`) suffice in MSH for MC4R, and the first 17 amino acids of ACTH are required for MC2R](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). Because four pockets recognize that short motif, chemists have faced [considerable difficulty developing highly selective ligands](https://pubmed.ncbi.nlm.nih.gov/26916163/).

## Receptor-by-receptor accounting: MC1R through MC5R

- **MC1R (skin, hair, and immune cells):** Located on cutaneous melanocytes—and on [leukocytes, where it may mediate anti-inflammatory effects](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/)—MC1R governs the balance between red *pheomelanin*, which [can generate free radicals under ultraviolet light](https://pubmed.ncbi.nlm.nih.gov/7581459/), and photoprotective black *eumelanin*. In 1995, Valverde and colleagues found human `MC1R` sequence variants in [over 80% of individuals with red hair, fair skin that tans poorly, or both, compared with fewer than 20% of brown- or black-haired individuals and less than 4% of good tanners](https://pubmed.ncbi.nlm.nih.gov/7581459/). A 2025 review (disclosing editorial assistance funded by Rhythm Pharmaceuticals) counts [roughly 200 identified allelic variants with about 60% prevalence among individuals of European ancestry](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/), and notes that MC1R signaling promotes UV-induced DNA nucleotide excision repair independently of melanin pigmentation.
- **MC2R (adrenal cortex):** The lone structural outlier. [ACTH is the only known endogenous ligand for MC2R, making it the sole agonist that stimulates all five MCRs](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/), and [the first 17 amino acids of ACTH are required for MC2R activation](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/); `α-`, `β-`, and `γ-MSH` [cannot bind or activate MC2R](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/). As [Yang (2011) details](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/), substituting phenylalanine-7 with D-phenylalanine (`D-Phe7`) in ACTH decreases ligand binding affinity and potency at MC2R, whereas substituting `Phe7` with `D-Phe` in MSH increases affinity and potency at MC1R, MC3R, MC4R, and MC5R.
- **MC3R and MC4R (hypothalamus and central nervous system):** Mouse knockout studies established nonredundant neural roles: [MC3R regulates feed efficiency, while MC4R controls both food intake and energy expenditure](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). Mice with targeted *MC4R* inactivation develop [maturity-onset obesity with hyperphagia, hyperinsulinemia, and hyperglycemia](https://pubmed.ncbi.nlm.nih.gov/9019399/). A year later, [Krude et al. (1998) documented the first two human probands with *POMC* mutations](https://pubmed.ncbi.nlm.nih.gov/9620771/), defining an endocrine triad of early-onset obesity, adrenal insufficiency, and red hair pigmentation. Central MC4R also participates in [brain pathways involved in sexual response](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/).
- **MC5R (exocrine glands):** Expressed across multiple human peripheral tissues and [implicated primarily in exocrine and sebaceous gland secretion in animal targeted-deletion studies](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/).

## EC50 potency at human receptors across the switchboard

Pharmacologists compare receptor activity using `EC50`—the concentration producing half-maximal activation in in vitro assays at human melanocortin receptors, reported in nanomolar (nM), where a lower number means higher potency. In vitro receptor `EC50` values do not measure blood-brain-barrier entry, implant release kinetics, or clinical exposure, but they expose the selectivity profile of each peptide.

**Figure 3 · EC50 at Human Receptors (Log Scale).** Lower `EC50` values toward the left reflect stronger activation at human melanocortin receptors. Data compiled from Table 3 of [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) (primary assay set from Kievit et al., 2013; *bremelanotide from Durek et al., 2018, where MC5R was not reported).

### EC50 Potency at Human Melanocortin Receptors (Yuan & Tao, 2022 Table 3; Kievit et al., 2013 & Durek et al., 2018*)

| Peptide | MC1R (nM) | MC3R (nM) | MC4R (nM) | MC5R (nM) |
|---|---|---|---|---|
| Native `α-MSH` | 1.01 | 1.04 | 4.7 | 10.5 |
| [Afamelanotide (NDP-MSH)](/afamelanotide-scenesse) | 0.462 | 0.109 | 0.075 | 0.253 |
| [Bremelanotide*](/bremelanotide-vyleesi) | 0.095 | 2.4 | 0.25 | Not reported |
| [Setmelanotide](/setmelanotide-imcivree) | 5.8 | 5.3 | 0.27 | 1600 |
| [Melanotan II](/melanotan-online-market) | 0.2 | 0.51 | 0.05 | 5.33 |

Two contrasts stand out in [Yuan and Tao's Table 3](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) (compiling Kievit et al., 2013, and *Durek et al., 2018 for bremelanotide). First, [Melanotan II](/case-reports-and-safety) acts as a [nonselective agonist with nanomolar to subnanomolar potency](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) across MC1R (0.2 nM), MC3R (0.51 nM), MC4R (0.05 nM), and MC5R (5.33 nM). Second, even linear afamelanotide shows subnanomolar potency at MC3R and MC4R in human-receptor assays—underscoring why clinical development relies on formulation control and tissue access as well as receptor affinity.

## Natural brakes, allosteric pockets, and biased signaling

Unlike many hormone receptors, melanocortins exhibit high basal activity. As King and colleagues note, [MCRs 1, 3, 4, and 5 maintain high constitutive (ligand-independent) activity](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/), allowing antagonists to decrease basal cyclic AMP levels. Two endogenous proteins fill that role: [agouti signaling protein (ASIP) selectively antagonizes MC1R and MC4R, while agouti-related protein (AgRP) selectively antagonizes MC3R and MC4R](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/).

As [Yingkui Yang (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/) defines the binding geometry, endogenous agonists bind the *orthosteric site*—the receptor area where natural ligands dock—whereas an *allosteric site* is distinct from that endogenous binding site. Modern MC4R drug design also examines biased signaling: [MC4R can couple to three major G-protein families (`Gs`, `Gi/o`, and `Gq`)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/). Earlier clinical MC4R obesity candidates [failed in human trials despite preclinical efficacy due to poor efficacy and side effects](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). By contrast, [setmelanotide](/setmelanotide-imcivree) [potently activates MC4R `Gαq` signaling that AgRP cannot efficiently antagonize](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/)—a pathway linked in preclinical studies to reduced food intake without cardiovascular pressor effects.

---

## Receptor Switchboard Key

- **Precursor Gene:** `POMC` — induced by UV-activated `p53` in skin keratinocytes; cleaved into melanocortins (ACTH, α/β/γ-MSH) plus opioid ligand β-endorphin
- **Activation Thresholds:** `His-Phe-Arg-Trp` for MC1R/MC3R/MC5R; `Phe-Arg-Trp` for MC4R; first 17 amino acids of ACTH for MC2R
- **Subtype Homology:** 38% to 60% sequence identity across human MC1R–MC5R (smallest known GPCR family)
- **D-Phe7 Substitution:** In ACTH, lowers affinity and potency at MC2R; in MSH, raises affinity and potency at MC1R, MC3R, MC4R, and MC5R (Yang, 2011)
- **Endogenous Antagonists:** `ASIP` (MC1R/MC4R) and `AgRP` (MC3R/MC4R), selective endogenous melanocortin antagonists (Yang, 2011)

### Prescription Medicines & Safety
- [03. Afamelanotide (Scenesse) · MC1R](/afamelanotide-scenesse)
- [04. Bremelanotide (Vyleesi) · MC1R/MC4R](/bremelanotide-vyleesi)
- [05. Setmelanotide (Imcivree) · MC4R](/setmelanotide-imcivree)
- [07. MT-II Case Reports & Safety](/case-reports-and-safety)

- Previous Dispatch · 01: [The Tucson Switchboard Accident](/tucson-origin)
- Next Dispatch · 03: [Afamelanotide (Scenesse)](/afamelanotide-scenesse)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [five-receptors.md](/five-receptors.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
